This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Inoue, K. Articles by Dinney, C. P. N. Search for Related Content PubMed PubMed Citation Articles by Inoue, K. Articles by Dinney, C. P. N.

Gene Therapy of Human Bladder Cancer with Adenovirus-mediated Antisense Basic Fibroblast Growth Factor¹

Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030

ABSTRACT

We previously investigated the role of basic fibroblast growth factor (bFGF) as a mediator of angiogenesis, tumorigenicity, and metastasis of transitional cell carcinoma (TCC) of the bladder. In the present study, we determined whether adenoviral-mediated antisense bFGF gene transfer therapy (Ad bFGF-AS) would inhibit TCCs growing in the subcutis of nude mice. In vitro, Ad bFGF-AS inhibited endothelial cell proliferation and enhanced apoptosis. The highly metastatic human TCC cell line 253J-BV^R was implanted ectopically in the subcutis of athymic nude mice, and therapy was begun when the tumors reached a diameter between 5 and 7 mm. Intralesional therapy with Ad bFGF-AS decreased the in vivo expression of bFGF and matrix metalloproteinase type 9 mRNA and protein, and reduced microvessel density and enhanced endothelial cell apoptosis. Tumor growth was significantly inhibited by Ad bFGF-AS (mean, 58 mg) compared with controls [saline (mean, 562 mg), ß-galactosidase adenovirus (mean, 586 mg), and sense bFGF adenoviral therapy (Ad bFGF-S; mean, 3012 mg)]. These results suggest that Ad bFGF-AS therapy affects endothelial cells directly and tumor cells indirectly through down-regulation of bFGF and matrix metalloproteinase type 9, resulting in endothelial cell apoptosis and significant tumor growth inhibition. Furthermore, these studies confirm that bFGF expression is a valid target for the therapy of bladder cancer.

This article has been cited by other articles:

				A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]

				P. J. Tebben, K. R. Kalli, W. A. Cliby, L. C. Hartmann, J. P. Grande, R. J. Singh, and R. Kumar Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors Mayo Clin. Proc., June 1, 2005; 80(6): 745 - 751. [Abstract] [PDF]

				X. Jiang and J. R. Couchman Perlecan and Tumor Angiogenesis J. Histochem. Cytochem., November 1, 2003; 51(11): 1393 - 1410. [Abstract] [Full Text] [PDF]

				K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin Docetaxel Enhances the Therapeutic Effect of the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Metastatic Human Transitional Cell Carcinoma Clin. Cancer Res., February 1, 2003; 9(2): 886 - 899. [Abstract] [Full Text] [PDF]

				K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin Frequent Administration of Angiogenesis Inhibitor TNP-470 (AGM-1470) at an Optimal Biological Dose Inhibits Tumor Growth and Metastasis of Metastatic Human Transitional Cell Carcinoma in the Urinary Bladder Clin. Cancer Res., July 1, 2002; 8(7): 2389 - 2398. [Abstract] [Full Text] [PDF]

				H. Miyake, I. Hara, S. Kamidono, and M. E. Gleave Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model Clin. Cancer Res., December 1, 2001; 7(12): 4245 - 4252. [Abstract] [Full Text] [PDF]